Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02683980 · ClinicalTrials.gov registry record · NA
Ablation Efficacy of Contact Side Firing Fiber in Predefined Settings for Treating BPH
A NA study of Treatment of Benign Prostatic Hyperplasia, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02683980: Completed NA study of Treatment of Benign Prostatic Hyperplasia, sponsored by Boston Scientific Corporation.
NCT02683980 is a NA study of Treatment of Benign Prostatic Hyperplasia that has completed, run by Boston Scientific Corporation. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02683980, a NA study of Treatment of Benign Prostatic Hyperplasia, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Twenty (20) subjects presenting with a hyperplasia enlarged prostate and candidates for surgery will undergo a single treatment for ablation of the prostate using the study device. Follow up visits are scheduled for the day of release from the hospital and at 1 and 3 months post procedure. The primary objective of this study is to explore Vaporization efficacy and safety when treating BPH (Benign prostatic hyperplasia) with the contact side firing fiber with recommended settings.
Primary Outcome
Calculate the lasing time (in minutes) to ablate the prostate as an indication for treatment efficiency.
Conditions Studied
Interventions
- DEVICE Lumenis Pulse P120H and Xpeeda side firing fiber
Study Locations (1)
New York
- New York Methodist Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-11-01 |
| Phase | NA |
What the finished NCT02683980 record still lists
NCT02683980 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Treatment of Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which Lumenis Pulse P120H and Xpeeda side firing fiber is the first listed.
NCT02683980 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02683980 about?
NCT02683980 is a clinical study titled "Ablation Efficacy of Contact Side Firing Fiber in Predefined Settings for Treating BPH". Twenty (20) subjects presenting with a hyperplasia enlarged prostate and candidates for surgery will undergo a single treatment for ablation of the prostate using the study device. Follow up visits are scheduled for the day of release from the hospital and at 1 and 3 months post procedure. The prim...
What is the current status of trial NCT02683980?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2016-02. Estimated completion is 2017-11-01.
What conditions does trial NCT02683980 study?
This clinical trial studies the following conditions: Treatment of Benign Prostatic Hyperplasia.
What interventions are being tested in trial NCT02683980?
The interventions under investigation include: Lumenis Pulse P120H and Xpeeda side firing fiber (DEVICE).
Who is sponsoring clinical trial NCT02683980?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02683980 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02683980's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia